Novel Antioxidant Can Provide a Number of Health Benefits for Peripheral Artery Disease According to 11 Patient Published Study

Lucida Medical (Cambridge University Spin-out) Joins GE Healthcare Edison™ Accelerator Programme

Lucida Medical was invited to join the Edison Accelerator programme for its pioneering work in helping identify prostate cancer and its exceptional development team led by Prof Evis Sala and Dr Antony Rix, both highly experienced in artificial intelligence, or AI, medical technology.

Boston Scientific Exercises Option to Acquire Farapulse, Inc.

FARAPULSE Pulsed Field Ablation (PFA) System is a non-thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias.  

November 20, 2020

Novel antioxidant can provide a number of health benefits for individuals with peripheral artery disease according to researchers at the School of Health and Kinesiology at the University of Nebraska at Omaha.

Novel antioxidant specifically targets mitochondria, considered the powerhouse of the cell. The study was led by Assistant Professor Song-Young Park, Ph.D., and published in the American Journal of Physiology-Heart and Circulatory Physiology.

Park recruited eleven men and women with PAD to participate in this research; six of which received 80 milligrams of the antioxidant while the remaining five participants were given a placebo. Measurements were done before and 40 minutes after each participant took the supplement or placebo to assess the roles of vascular mitochondria in endothelial function, arterial stiffness, exercise tolerance, and skeletal muscle function. After a 14 day “wash out” period, the two groups switched, with the placebo group taking the supplement and vice versa, and measurements were assessed again.

When a participant took the supplement, the researchers noted an increase in dilation of the arteries, popliteal flow-mediated dilation, antioxidant superoxide dismutase, maximal walking time and distance, and time to claudication or leg pain.

“The results of this study reveal for the first time that acute oral intake of a mitochondrial-targeted antioxidant is effective for improving vascular endothelial function and superoxide dismutase in patients with peripheral artery disease (PAD),” Park said. “This improvement is clinically important and such antioxidants may potentially be utilized as therapeutic supplement for patients with PAD”.

The novel antioxidant, commercially available as MitoQ, contains the naturally occurring ubiquinol which is a coenzyme that gives the antixoxidant the ability to cross the cell membrane and accumulate within the mitrochondria.

Peripheral artery disease (PAD) is a common cardiovascular disease in which atherosclerotic plaque forms in the arteries of the leg which can cause decrease blood flow and reduced perfusion in the lower extremity. The disease affects nearly 200 million people worldwide, with over 20 percent of individuals over 80 years old being affected by this disease. Common symptoms often include foot ulcers and leg pain during walking. If severe, medical treatment up to and including leg amputation may be required.

This study was funded in part by the University of Nebraska at Omaha Graduate Research and Creative Activity (GRACA) grant awarded to Jiwon Song, University of Nebraska at Omaha University Committee on Research and Creative Activity (UCRCA) awarded to Song-Young Park and the NASA Nebraska Space Grant (#NNX15AI09H) awarded to Song-Young Park. Doses of MitoQ were donated to UNO by MitoQ Limited for use in this research study.

Medical benefits



Trinity Health Names Mark LePage, M.D., as Senior Vice President of Medical Groups and Ambulatory Strategy

Prior to his time at IHA, LePage served as chief medical officer of Marshfield Clinic in Wisconsin

Jody Crane, MD Recognized by Modern Healthcare As One of the 50 Most Influential Clinical Executives

Dr. Crane’s work to streamline operations positioned and prepared TeamHealth and its clinicians to face the COVID-19 pandemic. Under Dr. Crane’s leadership, TeamHealth was able to maintain high levels of clinical quality throughout the rapidly changing COVID environment.

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

Subscribe to Medical Device News Magazine here.

Related Articles